Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 14

  • 844 clinical trials
  • 268 recruiting
  • 353 conditions
  • 25 countries

Conditions in this area

353 conditions with trials, the busiest first

Dermatitis atopic88Malignant melanoma79Systemic lupus erythematosus61Psoriasis53Hidradenitis47Psoriatic arthropathy46Systemic scleroderma39Metastatic malignant melanoma32Vitiligo23Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis15Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Diabetic foot13Basal cell carcinoma12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+329

Clinical trials in Skin and subcutaneous tissue disorders

844 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

844 clinical trials

Squamous cell carcinoma of head and neck+7

Recruiting

Study on PET Imaging with Fianlimab and Cemiplimab for Patients with Advanced Solid Tumors, with or without Platinum-Based Chemotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Universitair Medisch Centrum Groningen

Squamous cell carcinoma of skin

Recruiting

Study on Cemiplimab for Patients with High-Risk Stage III/IV Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Fondazione Melanoma Onlus

Systemic lupus erythematosus

Recruiting

Study on the Effects of Belimumab for Patients with Systemic Lupus Erythematosus (SLE)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Amsterdam UMC Stichting

Pyoderma

Recruiting

Study on Short vs. Standard Amoxicillin Treatment for Adults with Lower Limb Erysipelas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Hereditary angioedema

Recruiting

Long-Term Safety Study of Berotralstat for Patients with Hereditary Angioedema from Previous Trials

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Berotralstat
  • Sponsor:Biocryst Pharmaceuticals Inc.

Acute lymphocytic leukaemia+2

Recruiting

Long-term Safety Study of AUTO4 and Rituximab in Patients with Potential Malignancy Treated with Autologous CAR T Cell Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Auto4
  • Sponsor:Autolus Limited

Thermal burn

Recruiting

Study on the Effectiveness of EHSG-KF Skin Graft for Patients with Deep Partial and Full-Thickness Burns

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bilayer Engineered Collagen Hydrogel-Based Skin Graft Composed Of Autologous Keratinocytes And Fibroblasts
  • Sponsor:Cutiss AG

Wiskott-Aldrich syndrome

Recruiting

Long-Term Safety Study of Gene Therapy with Etuvetidigene Autotemcel for Patients with Wiskott-Aldrich Syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Etuvetidigene Autotemcel
  • Sponsor:Genethon

Pemphigoid

Recruiting

Study on the Effect of Clobetasol Propionate on Bone Mineral Density in Patients with Bullous Pemphigoid

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Clobetasol Propionate
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Non-small cell lung cancer+1

Recruiting

Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dabrafenib Mesylate
  • Sponsor:Novartis Pharma AG

Toxic epidermal necrolysis+1

Recruiting

Study on Filgrastim for Patients with Severe Bullous Drug Eruptions: Lyell and Stevens-Johnson Syndromes

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Hospices Civils De Lyon

Squamous cell carcinoma of skin

Recruiting

Study of Nivolumab and Nivolumab Plus Relatlimab for Patients with Advanced or Metastatic Skin Squamous Cell Carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.